Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Coherus BioSciences Inc CHRS

Coherus BioSciences, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the research, development and commercialization of immunotherapies to treat cancer. The Company’s immuno-oncology pipeline includes multiple antibody immunotherapy candidates focused on enhancing the innate and adaptive immune responses to enable a robust antitumor immunologic response and... see more

Recent & Breaking News (NDAQ:CHRS)

Coherus BioSciences Reports Third Quarter 2014 Financial and Operating Results

GlobeNewswire December 15, 2014

Coherus BioSciences to Present at the J.P. Morgan Healthcare Conference on January 12

GlobeNewswire December 8, 2014

Coherus BioSciences to Host Earnings Conference Call on December 15

GlobeNewswire December 4, 2014

Coherus BioSciences Announces Closing of Initial Public Offering and Exercise of Underwriters' Option to Purchase Additional Shares

GlobeNewswire November 12, 2014

Coherus BioSciences Prices Initial Public Offering of $85 Million of Common Stock

GlobeNewswire November 6, 2014